Clinical trial
Erlotinib and Temozolomide in Treating Young Patients With Recurrent or…
NCT00077454 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00077454 |
|---|---|
| Title | Erlotinib and Temozolomide in Treating Young Patients With Recurrent or Refractory Solid Tumors |
| Official title | A Phase I Study of Single Agent OSI-774 (Tarceva) (NSC# 718781, IND# 63383) Followed by OSI-774 With Temozolomide for Patients With Selected Recurrent/Refractory Solid Tumors, Including Brain Tumors |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Previously Treated Childhood Rhabdomyosarcoma, Recurrent Childhood Brain Tumor, Recurrent Childhood Cerebellar Astrocytoma, Recurrent Childhood Cerebral Astrocytoma, Recurrent Childhood Ependymoma, Recurrent Childhood Malignant Germ Cell Tumor, Recurrent Childhood Medulloblastoma, Recurrent Childhood Rhabdomyosarcoma, Recurrent Childhood Soft Tissue Sarcoma, Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor and 2 more |
| Intervention type | Drug, Other |
| Interventions | erlotinib hydrochloride, temozolomide, pharmacological study, laboratory biomarker analysis |
| Enrollment | 95 |
| Start date | Feb 1, 2004 |
| Primary completion | Sep 1, 2007 |
| First posted | Feb 12, 2004 |
| Last update posted | Jun 5, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: